Medtronic
MDT
Market cap $115B

89.79 USD

-0.20

0.22%

At close Oct 17, 4:00 PM EDT

After hours

90.10

+0.31

0.35%

1 day

-0.22%

5 days

0.91%

1 month

1.31%

3 months

10.50%

6 months

13.54%

Year to date

8.39%

1 year

23.32%

5 years

-17.25%

About: One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Employees: 95,000

Healthcare Electromedical & Electrotherapeutic Apparatus

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 15 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

32% more call options, than puts

Call options by funds: $652M | Put options by funds: $492M

3% less repeat investments, than reductions

Existing positions increased: 805 | Existing positions reduced: 827

2.52% less ownership

Funds ownership: 83.51% [Q1] → 80.99% (-2.52%) [Q2]

3% less funds holding

Funds holding: 2,040 [Q1] → 1,986 (-54) [Q2]

13% less capital invested

Capital invested by funds: $96.6B [Q1] → $83.6B (-$13B) [Q2]

23% less funds holding in top 10

Funds holding in top 10: 31 [Q1] → 24 (-7) [Q2]

28% less first-time investments, than exits

New positions opened: 138 | Existing positions closed: 192

See Fund Rankings

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$85

5%

downside

Avg. target

$95

6%

upside

High target

$106

18%

upside

15 analyst ratings

5 positive

33%

10 neutral

67%

0 negative

0%

Truist Securities Richard Newitter 66% 1-year accuracy 29 / 44 met price target	4%upside $93	Hold Maintained	14 Oct 2024
RBC Capital Shagun Singh 68% 1-year accuracy 40 / 59 met price target	17%upside $105	Outperform Upgraded	10 Oct 2024
RBC Capital Shagun Singh 68% 1-year accuracy 40 / 59 met price target	9%upside $98	Sector Perform Maintained	8 Oct 2024
Evercore ISI Group Vijay Kumar 76% 1-year accuracy 29 / 38 met price target	16%upside $104	Outperform Maintained	1 Oct 2024
Citigroup Joanne Wuensch 72% 1-year accuracy 23 / 32 met price target	2%upside $92	Neutral Maintained	1 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 21 articles about MDT published over the past 30 days

Zacks Investment Research

Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the latest trading session, Medtronic (MDT) closed at $89.36, marking a +0.57% move from the previous day.

Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Medtronic: Undervalued Dividend Aristocrat With High Margins

Medtronic remains an attractive investment due to its diversified revenue streams, robust product pipeline and improving margins. MDT's growth is driven by strong performance in Neuroscience, Cardiovascular, and Diabetes care, with significant international revenue growth and a promising product pipeline. Trading below its historical valuation, MDT offers a compelling opportunity for conservative investors seeking quality at a reasonably low price.

Medtronic: Undervalued Dividend Aristocrat With High Margins

Zacks Investment Research

MDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?

The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.

MDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?

Buy 4 October Dividend Aristocrats & Watch 10

"Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 10.5%-20.13% topped-by Franklin & Target.

Buy 4 October Dividend Aristocrats & Watch 10

Zacks Investment Research

The Zacks Analyst Blog JPMorgan, Medtronic, Shopify and Perma-Pipe International

JPMorgan, Medtronic, Shopify and Perma-Pipe International are included in this Analyst Blog.

The Zacks Analyst Blog JPMorgan, Medtronic, Shopify and Perma-Pipe International

Zacks Investment Research

Medtronic (MDT) Advances But Underperforms Market: Key Facts

Medtronic (MDT) concluded the recent trading session at $88.26, signifying a +0.56% move from its prior day's close.

Medtronic (MDT) Advances But Underperforms Market: Key Facts

Medtronic voluntarily recalls insulin pumps due to risk of shortened battery life

Company says the smallest knock can impact batteries by damaging internal electronics

Medtronic voluntarily recalls insulin pumps due to risk of shortened battery life

Voluntary recall notifying Medtronic insulin pump users of potential risks of shortened pump battery life

Customers are being notified of the importance of checking built-in alerts and alarms for battery status and to contact Medtronic for pump replacement if affected by this issue GALWAY, Ireland , Oct. 4, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump. Medtronic began investigating this issue upon receiving customer reports of shortened battery life and a comprehensive analysis found that pumps that have been dropped, bumped, or experienced physical impact even once may result in shortened battery life due to damage to internal electrical components.

Voluntary recall notifying Medtronic insulin pump users of potential risks of shortened pump battery life

Mexico Spinal Implants Market Size, Share & Trends Analysis 2024-2030, with Focus on Market Leaders ZimVie/Highridge Medical, Medtronic and DePuy Synthes

Dublin, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The "Mexico Spinal Implants Market Size, Share & Trends Analysis | 2024-2030 | MedSuite | Includes: Cervical Fixation Market, Thoracolumbar Fixation Market, and 4 more" report has been added to ResearchAndMarkets.com's offering. In 2023, Mexico's spinal implant and VCF market reached a valuation exceeding $135 million. Projected to grow at a CAGR of 6.1%, the market is expected to surpass $205 million by 2030. This comprehensive report on the Mexican spinal implant and VCF market covers various segments, including traditional cervical and thoracolumbar fixation devices, interbody devices, motion preservation devices, VCF treatment, electrical stimulation devices, and spinal surgery instrumentation. Key Market Data Insights:

Mexico Spinal Implants Market Size, Share & Trends Analysis 2024-2030, with Focus on Market Leaders ZimVie/Highridge Medical, Medtronic and DePuy Synthes

Zacks Investment Research

Reasons to Retain Medtronic Stock in Your Portfolio Now

Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.

Reasons to Retain Medtronic Stock in Your Portfolio Now

See News Rankings

Charts implemented using Lightweight Charts™